HUNT VALLEY, Md., July 11, 2016 /PRNewswire/ -- Pharmaceutics International, Inc. (Pii), a Contract Development Manufacturing Organization (CDMO) based in Hunt Valley, Maryland (http://www.pharm-int.com/), has announced that Matthew Giles has been appointed Vice President of Data Integrity and Quality Control.
Matthew Giles has over 20 years of experience in overseeing laboratory operations at Actavis, Qualitest, King Pharmaceuticals, Alpharma, and Hospira. He has extensive experience in both Research and Development and Quality. Prior to joining Pii, he has been providing data integrity consulting services to the pharmaceutical industry. He has joined Pii as the Vice President of Data Integrity and Quality Control reporting directly to the President and CEO, Syed Abidi, PhD.
Dr. Syed Abidi, commented, "We are delighted to have someone with Matt's experience joining Pii. This newly created position, and the experience that Matt brings to it, highlights our commitment to the importance of data integrity in today's regulatory environment."
About Pharmaceutics International, Inc.
Pii is a privately held CDMO providing dosage form development and GMP manufacturing services to the global pharmaceutical industry. Headquartered in Hunt Valley, Maryland USA with European facilities in the UK, services include pre-formulation testing, formulation development, clinical and commercial GMP manufacturing of solid, parenteral, inhalation, semi-solid and liquid dosage forms, clinical packaging and labeling, clinical trial kit building and distribution, analytical and QP services. Pii's facilities include manufacturing and containment suites, automated packaging lines and a wide selection of equipment. For more information, please visit www.pharm-int.com.
Steve King, Senior Vice President
Pharmaceutics International, Inc.
10819 Gilroy Road
Hunt Valley, MD 21031
Phone: (410) 584-0001
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/matthew-giles-vice-president-data-integrity-and-quality-control-300296393.html
SOURCE Pharmaceutics International, Inc.